Back

Effect of empagliflozin with or without sacubitril/valsartan on the lipoprotein, glycoprotein and lipid profile in a porcine model of myocardial infarction

14 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Basic science Drugs, Drug Targets HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Daina Martinez-Falguera

Health Science Research Institute Germans Trias i Pujol (IGTP), Badalona (Spain)

4 More presentations in this session

Presentation thumbnail
CDK4/6 inhibitor ribociclib induces cardiotoxicity in dynamic engineered heart tissues, mitigated by E2F1 overexpression
Mr I. Dias (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Unravelling the diversity of cholinesterases in the murine heart as an essential prerequisite for the use of cholinesterase inhibitors in the treatment of heart failure
Associate Professor A. Hrabovska (Bratislava, SK)
Abstract Slides Video
Presentation thumbnail
Cellular phenotyping of structural and functional changes in atrial myopathy
Doctor J. Huettemeister (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Non-dilated left ventricular cardiomyopathy with arrhythmias is caused by the nonsense founder variant DSP:c.3793G>T in Slovenian patients
Ms N. Vodnjov (Ljubljana, SI)
Abstract Slides Video

Access the full session

Session thumbnail
Basic science

The Event

Event poster

Heart Failure 2024

14 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Investigating the effects of empagliflozin on myocardial metabolic and lipid profile in healthy and metabolic syndrome murine models following acute myocardial infarction
thumbnail
Congress Presentation
Effects of LCZ696 on lipid metabolism in an animal model of heart failure with preserved ejection fraction (HFpEF). Possible implications for the management of obesity associated with HFpEF.
thumbnail
Congress Presentation
Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources